Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | MB | P02144 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17926499 | 0.81 | SRC (0.43) | SRCCMA1AHR | |
| SCHEMBL2453854 | 0.81 | SRC (0.56) | SRCPDE3BPDE3ACMA1AHR | |
| SCHEMBL18103980 | 0.69 | SRC (1.00) | SRCPDE3BPDE3AMBHPGD | |
| SCHEMBL12382071 | 0.68 | SRC (0.46) | SRCPDE3BPDE3AMBHPGD | |
| SCHEMBL13244249 | 0.67 | SRC (0.41) | SRCCMA1AHR | |
| SCHEMBL17610918 | 0.65 | SRC (0.33) | SRC | |
| SCHEMBL22061405 | 0.64 | SRC (0.46) | SRCPDE3BPDE3A | |
| SCHEMBL29319846 | 0.64 | — | — | |
| SCHEMBL4764114 | 0.64 | SRC (0.42) | SRCPDE3BPDE3AMB | |
| SCHEMBL661744 | 0.63 | KDR (0.42) | PDE3BPDE3ACMA1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | USP1, USP2, USP3 | SRC 2859/4885PDE3B 2997/4885PDE3A 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.